Total Voting Rights

RNS Number : 9425J

Renalytix PLC

29 April 2022

 

Renalytix plc  

("Renalytix" or the "Company")  

Total voting rights

NEW YORK and SALT LAKE CITY, 29 April, 2022 - Renalytix (LSE: RENX) announces that the Company's total issued share capital consists of 74,760,432 shares of 0.25 pence each, with each share carrying the right to one vote. Renalytix does not hold any shares in treasury. The total number of voting rights in the Company following Admission will therefore be 74,760,432.

The figure of 74,760,432 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the FCA's Disclosure and Transparency Rules.

For further information, please contact:

Renalytix plc			www.renalytix.com
James McCullough, CEO			Via Walbrook PR
Stifel (Nominated Adviser, Joint Broker)			Tel: [phone]
Alex Price / Nicholas Moore
Investec Bank plc (Joint Broker)			Tel: [phone]
Gary Clarence / Daniel Adams
Walbrook PR Limited	Tel: [phone]  or    [e-mail]
Paul McManus / Lianne Applegarth / Alice Woodings		Mob: [phone]
CapComm Partners		Tel: [phone]  or [e-mail]
Peter DeNardo

About Renalytix

Renalytix (LSE: RENX) (NASDAQ: RNLX) is the global founder and leader in the new field of bioprognosis™ for kidney health. The company has engineered a new solution that enables early-stage chronic kidney disease progression risk assessment. The Company's lead product, KidneyIntelX™, has been granted Breakthrough Designation by the U.S. Foodand Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com). For more information, visit www.renalytix.com .

 

END

 

 

TVRBKCBQPBKDPQB